Long-term follow-up after 18 months of oral immunotherapy for peanut, egg, or milk allergy (5–15 years later)
Long Term Outcomes Associated With Attainment of Remission Following Oral Immunotherapy to Peanut, Egg and Cow's Milk (LPEM Study)
Murdoch Childrens Research Institute · NCT07359183
This follow-up will see if children and young people who completed an 18-month oral immunotherapy for peanut, egg, or milk allergy still have changes in allergy tests and better quality of life 5–15 years later.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 147 (estimated) |
| Sex | All |
| Sponsor | Murdoch Childrens Research Institute (other) |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Parkville, Victoria) |
| Trial ID | NCT07359183 on ClinicalTrials.gov |
What this trial studies
The study invites former participants from four OIT parent trials (PEAT, PrEMO, PPOIT-001, PPOIT-002) for a single clinic visit 5–15 years after finishing an 18-month OIT course. Visits include a blood draw for specific IgE, storage of plasma and PBMC for future research, a skin prick test, and allergy and quality-of-life questionnaires. The primary comparison is long-term health-related quality of life and allergy status in participants who achieved remission versus those who did not. Eligibility requires prior participation in one of the listed parent trials and receipt of at least one OIT dose.
Who should consider this trial
Good fit: Children and young people who previously enrolled in PEAT, PrEMO, PPOIT-001, or PPOIT-002 and received at least one dose of OIT are ideal candidates.
Not a fit: People who did not receive OIT in the parent trials or who cannot safely provide blood or undergo skin testing are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the study could clarify whether OIT produces durable remission and sustained quality-of-life improvements years after treatment, informing long-term care decisions.
How similar studies have performed: Previous OIT trials have demonstrated short-term desensitization and some longer-term remission signals, but comprehensive 5–15 year follow-up data remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Previous participant of PEAT, PrEMO, PPOIT-001 or PPOIT-002 parent study * Received at least one dose of OIT treatment in the parent study * Written informed consent from participant and/or parent/guardian (if below 18 years of age) Exclusion Criteria: -Have any conditions that, in the opinion of the investigator, precludes participation for reason of safety
Where this trial is running
Parkville, Victoria
- Murdoch Children's Research Institute — Parkville, Victoria, Australia (RECRUITING)
Study contacts
- Principal investigator: Adriana Chebar Lozinsky Rolnik — Murdoch Childrens Research Institute
- Study coordinator: Adriana Chebar Lozinsky Rolnik
- Email: lpem.study@mcri.edu.au
- Phone: 61399366435
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Food Allergies, Peanut Allergies, Egg Allergy, Milk Allergy